Research Partnership shortlisted for BHBIA BOBI Award
We are delighted to announce that the Research Partnership was recently shortlisted for a BHBIA (British Healthcare Business Intelligence Association) BOBI Award in the category “Agency I would most like to work in” sponsored by Janssen.
Sue Rees, Director in our European Division was present to accept the certificate at this year’s BHBIA Conference at The Grove Hotel in Watford. In order to attract and retain the most talented researchers, we endeavour to make the Research Partnership a great place to work. Consequently, we were very pleased to be shortlisted for this Award. Our thanks to all those who voted for us.
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis
Mary Assimakopoulos, eyeforpharma 14th May 2013
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards their standard of care. In this month’s column we discuss how promoting earlier diagnosis of a chronic disease, such as Psoriatic Arthritis (PsA), should result in better patient outcomes and generate a larger treatment market. PsA is an auto-immune disease which causes inflammation of the joints, pain and stiffness, which is accompanied by patches of red and white, scaly skin indicative of Psoriasis.PsA gets progressively worse and can cause permanent damage to the joints. These worsening skin manifestations can have a severe impact on a patient’s quality of life, particularly if located in highly visible parts of the body. Almost a third of people with psoriasis will develop PsA but patients may experience arthritic symptomsbefore any skin manifestations. The exact causes of the disease are not yet known, but a number of genetic associations have been identified. Because prolonged inflammation can lead to joint damage, early diagnosis and treatment is recommended and yet, in our patient research findings (carried out amongst people diagnosed with PsA across Europe), we have found…
Rx insights: Harnessing the strengths of mobile research in pharma
Published in PME May 2013 By John Branston, Director
Despite advances in data collection techniques and technology over the years, it has remained hard for global pharma to get immediate detailed, qualitative insights into prescribing rationale at the patient level, particularly where these prescription decisions are made by hospital specialists. This is an area where mobile research is now demonstrating clear advantages, because of functionality afforded by smartphone technology and the ubiquity of smartphones amongst physicians and in the clinical setting.
PBIRG Annual National Conference 2013
Naples, Florida, US May 19 -22, 2013
We were delighted to be exhibiting and presenting a paper at this year’s PBIRG Annual General Meeting in Naples, Florida. Directors Tom Winter and Claire Richardson took to the stage to present the paper 'I Just Want to Lead a Normal Life - Harnessing Mobile Research Methods to Improve Our Understanding of Compliance.' The paper looked at the limitations of existing research methods measuring compliance and investigated the use of mobile as a means of delivering better insights.